Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says
Yahoo · 29 de oct de 2026
Biogen (BIIB) has swung back to growth as shown by its solid Q3 results, RBC analysts wrote in a not
Biogen Inc.
BIIB
Sí, existe CEDEAR de BIIB en Argentina. Operás bajo el ticker BIIB en BYMA, con ratio 13:1 respecto a la acción en NASDAQ. Ratios y calculadora.
Empresa subyacente
HealthcareDrug Manufacturers - General
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
- País
- United States
- Empleados
- 7.500
- Sitio web
- biogen.com
Precio histórico
Últimos 235 días · 12/11/25 — 29/10/26
+74.66%
Cotización y datos
NASDAQRatio 13:1 · Subyacente BIIB
CEDEAR (ARS)
Precio
$ 32.460
Var. %
+2,4%
Volumen operado
1.842
Subyacente (USD)
Precio BIIB
US$ 253,69
Teórico (precio / ratio)
BIIB ÷ 13
US$ 19,51
Dólar MEP (BIIBD)
Preguntas frecuentes
¿Existe CEDEAR de BIIB en Argentina?
Sí, existe el CEDEAR de BIIB (Biogen Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es BIIB.
¿Cuál es el ticker del CEDEAR de Biogen Inc.?
El ticker del CEDEAR de Biogen Inc. en Argentina es BIIB. La acción subyacente cotiza en NASDAQ con el símbolo BIIB.
¿Cuál es el ratio del CEDEAR BIIB?
El CEDEAR BIIB tiene un ratio de 13:1. Eso significa que 13 CEDEARs equivalen a 1 acción de BIIB.
¿Cuánto vale el CEDEAR BIIB hoy?
El CEDEAR BIIB cotiza hoy a $ 32.460 en pesos argentinos, con una variación diaria de +2,4%.
¿Cuánto vale la acción BIIB en dólares?
CEDEARs similares
Otros CEDEARs de Salud.
Noticias
Alphabet downgraded, eBay upgraded: Wall Street's top analyst calls
Yahoo · 29 de oct de 2026
Alphabet downgraded, eBay upgraded: Wall Street's top analyst calls
Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive
SeekingAlpha · 29 de oct de 2026
Eli Lilly and Company remains a Buy, as its Q3 results show strong revenue growth and rising Mounjaro and Zepbound sales. Click for a detailed LLY update.
